Other Therapeutic Candidates

TTX-siPDL1
TTX-siPDL1 is a therapeutic candidate in development with TransCode to target PD-1/PD-L1. As traditional checkpoint inhibitors simply block PD-1/PD-L1 from binding each other, they may be ineffective in many cancers, including pancreatic cancer. However, TTX-siPDL1 employs an RNAi approach with the intention of preventing the synthesis of PD-L1 altogether instead of blocking its function.

As a result of successful animal studies, TTX-siPDL1 has received Orphan Designation Status from FDA for pancreatic cancer.
​
Learn more about TTX-siPDL1:

Download

preview

---

​64Cu-TTX-MC138
The use of radioisotopes is a (re)emerging approach for many drug development companies in the treatment of cancer. TransCode believes our TTX has the potential for efficient localized penetration of radioisotopes inside tumor cells. 64Cu-TTX-MC138 has potential benefits that include:

• PK profile that minimizes off-target exposure, maximizes high tumor uptake
• Achieves localization, penetration, and persistence across tumor histologies while maximizing systemic clearance
• Deeper tumor penetration to enable more homogeneous irradiation of tumor mass
• Achieving the above enables use of off-target toxicity reducing short-range alpha emitters

In pre-clinical studies, delivery of 64Cu-TTX-MC138 to metastatic sites has already been demonstrated; a first-in-human microdosing study is anticipated in 1Q 2023. 

Learn more about 64Cu-TTX-MC138:

download

preview

---

TTX-RIGA
Immunotherapy represents a powerful alternative to traditional clinical treatments for cancer. Recent developments in the use of Pattern Recognition Receptors, or PRRs, specifically retinoic acid-inducible gene I-like receptors (RIG-I), aim to harness the innate power of the immune system for anti-cancer therapy. TTX-RIGA is in development to target cancer via the RIG-I signaling pathway. Delivery of TTX-RIGA combines with a tumor specific RNA inside tumor cells to produce  a potent agonist of the RIG-I signaling pathway.

RIG-I engagement has been shown to promote tumor cell death, and to activate the innate and adaptive immune systems. These factors suggest it could be an attractive therapeutic approach in oncology.

​Learn more about TTX-RIGA:

download

preview

---

TTX-siLIN28B
TTX-siLIN28B is in development to target multiple solid tumors. LIN28B is a biomarker of tumor survival and an actionable therapeutic target for solid tumors. 

Learn more about TTX-siLIN28B:

download

Preview

Additional TTX Therapeutic Opportunities Being Explored in Our Lab

• TTX can be designed to deliver CRISPR/Cas9 therapy inside tumor cells to delete and/or repair cancer-causing gene sequences (TTX-CRISPR). 

• TTX-mRNA, a messenger RNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.

---

Diagnostics
We are also studying approaches for early cancer detection.

download

preview

TransCode executed exclusive option agreements with Massachusetts General Hospital (MGH), for TTX-siLin28b and 64Cu-TTX-MC138, under which TransCode has the right to negotiate an exclusive license for these assets.